Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Study Shows Consistent Use Of Insulin Pump Therapy, Augmented With Continuous Glucose Monitoring, Results In Significant A1C Reductions
Medtronic, Inc. (NYSE: MDT) announced results of a randomized, controlled trial to demonstrate the benefits of an insulin pump therapy augmented with real-time continuous glucose monitoring (Personal CGM) versus a conventional pump and self-monitoring of blood glucose in type 1 diabetes patients with poor metabolic control. Study findings showed that patients who used Personal CGM more than 70 percent of the time achieved nearly a full percentage point reduction in A1C (average blood glucose levels). The results were presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans. Don't forget to buy zoloft online no prescription.

Shreveport, La., Center Continues To Provide HIV/AIDS Services After 20 Years
The Shreveport Times profiled the 20-year-old Shreveport, La.-based Philadelphia Center, an agency that provides HIV/AIDS services to "an average of nearly 600 people each year in northwest Louisiana" and provides "about 1,400 free HIV tests each year." The organization also has a residential program called the Mercy Center, "a haven for homeless people with HIV or those fighting addiction and other challenges," according to the Times. The center in large part is supported by an annual auction from which proceeds "help the agency operate support groups, coordinate medical, dental and housing services for clients, provide food and medicine to people and offer free, on-the-spot HIV testing," the article states. The center recently opened a satellite office in a nearby town in response to an increase in HIV infections in the area (Brumble 8/2).

generic viagra online


News of the day
University Of Kentucky's Markey Cancer Center Brings Advanced TomoTherapySM Treatment Technology To Brain And Body Radiosurgery Program
TomoTherapy Incorporated (NASDAQ: TOMO) announced that the University of Kentucky (UK) Chandler Medical Center"s Markey Cancer Center has commenced treating patients with the TomoTherapy® Hiò€¢Art® treatment system, a versatile, CT scanner-based device, which integrates image guidance for increased treatment accuracy and helical radiation therapy delivery for enhanced tumor targeting. The Hiò€¢Art treatment system was selected after a thorough review of technologies and will be extensively utilized in the Markey Cancer Center"s stereotactic body radiation therapy (SBRT) efforts, as part of its new Brain and Body Radiosurgery Program.
Mental Health

Another JDRF Partner Moves Research Forward With Collaboration Agreement For Diabetes Treatment

The Juvenile Diabetes Research Foundation said recently that for the fourth time in 18 months, one of its biotech partners has signed a collaboration agreement with a large pharmaceutical company to move research on type 1 diabetes into the final phases of trials. According to JDRF, a leader in setting the agenda for diabetes research worldwide and the largest charitable funder and advocate of type 1 diabetes research, the development is the latest success in its innovative Industry Discovery and Development Partnership (IDDP) program, through which JDRF provides early stage research funding to biotech companies working on technologies and therapeutic candidates. In the most recent success, JDRF industry partner Bayhill Therapeutics Inc., based in California, entered into a collaboration agreement with Genentech, Inc., a wholly owned member of the Roche Group, to further develop and potentially commercialize a novel antigen-specific immunotherapeutic designed to reverse the immune response that causes type 1 diabetes. To date, JDRF has awarded more than $29 million in research funding to 25 companies through its IDDP program. JDRF supported the ongoing Bayhill clinical trial with an IDDP grant in October of 2008. "We began the IDDP program to help small companies demonstrate proof-of-principle for innovative ideas and products to treat and cure type 1 diabetes, in order to attract funding for potential commercialization from large drug companies," said Alan J. Lewis, PhD, President and Chief Executive Officer of JDRF. "This latest agreement further demonstrates that the strategy is successful in accelerating the pace of research leading to a cure for diabetes." Dr. Lewis noted that the development underscores JDRF"s unique role helping to accelerate and translate research discoveries into cures and better treatment of type 1 diabetes and its complications. By supporting early stage research at small biotech companies, JDRF looks to lower the risk for larger pharmaceutical companies to create biotech partnerships and carry the products through expensive, late-stage trials and regulatory approvals. The goal, he said, is to bring cures and treatments for type 1 diabetes to market faster. Other IDDP partners that have created similar agreements include: Tolerx, based in Massachusetts, which has joined with GlaxoSmithKline to develop an anti-CD3 antibody to preserve beta cell function in newly diagnosed patients; Maryland-based MacroGenics, which is developing a similar antibody with Lilly; and Canada"s Transition Therapeutics, which has signed a commercialization agreement for a beta cell regenerative therapy with Lilly. Bayhill"s BHT-3021 compound is now in Phase I/II clinical trials supported by JDRF, is a plasmid encoding proinsulin designed to target specific pathogenic immune cells involved in the immune response of type 1 diabetes. About Type 1 Diabetes Type 1 diabetes is an autoimmune disease that affects children, adolescents, and adults, in which the immune system attacks cells in the pancreas that produce insulin, a hormone that enables people to convert food into energy. People with type 1 diabetes are dependent on insulin for the rest of their life. But insulin is not a cure, and people with diabetes are at significant risk for a wide range of serious complications, including heart disease, blindness and kidney disease. As many as 3 million people in the U.S. have type 1 diabetes. William Ahearn Juvenile Diabetes Research Foundation International


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009